Heart HealthClinical TrialPaywall

Novartis tests two anti-inflammasome drugs in heart disease patients with CHIP mutations

A completed Phase 2a trial tested DFV890 and MAS825 to lower IL-6 and IL-18 in coronary disease patients carrying TET2 or DNMT3A CHIP. No results are posted.

Saturday, November 21, 2026 1 view
Published in ClinicalTrials.gov
a clinician drawing a blood sample from a patient's arm in a clinic, with labeled sample tubes on a tray

Summary

Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition in which blood stem cells acquire mutations, often in TET2 or DNMT3A, and expand. It is linked to higher heart disease risk, and a leading mechanism is overactive inflammation driven by the inflammasome, producing IL-1beta, IL-18 and IL-6. This Phase 2a trial, sponsored by Novartis, tested two drugs aimed at that pathway: DFV890, an oral daily pill given for 12 weeks at increasing doses, and MAS825, a single subcutaneous injection. About 28 adults with known coronary heart disease and TET2 or DNMT3A CHIP (variant allele frequency of at least 2%) were enrolled. The goal was to see whether the drugs lower inflammatory markers tied to cardiovascular risk, and whether they are safe and tolerated. The trial is listed as completed, but the record gives no results. We do not yet know if either drug lowered inflammation, let alone whether it changes heart outcomes.

0:00--:--

Detailed Summary

Why it matters: CHIP becomes more common with age and is associated with higher risk of coronary disease. Carriers of TET2 and DNMT3A mutations have mutated blood cells that appear to produce excess inflammatory signals in the arterial wall. That makes CHIP a rare case where an aging-related genetic state points to a specific, druggable inflammatory target.

What was studied: This Phase 2a trial, sponsored by Novartis, evaluated two agents for efficacy, safety and tolerability. DFV890 is an oral daily drug, tested at increasing dose strengths for 12 weeks. MAS825 was given as a single subcutaneous dose, with a matching placebo listed. The primary aim was reducing inflammatory markers tied to cardiovascular risk, notably IL-6 and IL-18. Enrollment was approximately 28 adults with known coronary heart disease and TET2 or DNMT3A CHIP at a variant allele frequency of at least 2%.

Key results: None are available. The registry entry lists the study as completed but the information supplied contains no outcome data, no effect sizes and no safety findings. Any statement about whether the drugs worked or caused harm would be speculation.

Implications: The design is a mechanism-first test. The endpoints are surrogate inflammatory biomarkers, not heart attacks or death, so a positive result would show target engagement in a genetically defined group rather than clinical benefit. Still, it is worth watching because it tests whether blocking inflammasome-related signaling can quiet CHIP-driven inflammation in people. Larger and longer trials would be needed to link biomarker changes to outcomes.

Caveats: This summary rests on the registry abstract only. The sample is small, the study is early phase, and the exact mechanistic targets of each drug are not described in the supplied text. Results, dosing details and adverse events must be checked once published.

Key Findings

  • Phase 2a trial of oral DFV890 (12 weeks, increasing doses) and single-dose subcutaneous MAS825 in about 28 adults.
  • Population: coronary heart disease with TET2 or DNMT3A CHIP at variant allele frequency of at least 2%.
  • Primary focus is lowering inflammatory markers such as IL-6 and IL-18, which are surrogate markers, not clinical outcomes.
  • Status is completed, but no efficacy or safety results are included in the available record.
  • No evidence yet that either drug lowers inflammation, improves heart outcomes, or is free of harm in people with CHIP.

Methodology

Phase 2a interventional trial sponsored by Novartis, with ascending doses of oral DFV890 over 12 weeks and a single subcutaneous dose of MAS825 versus placebo. Planned enrollment was about 28 adults with coronary heart disease and TET2 or DNMT3A CHIP (VAF at least 2%). Endpoints center on inflammatory biomarkers (IL-6, IL-18), safety and tolerability.

Study Limitations

This summary is based on the registry abstract only; no results, doses, safety data or detailed endpoints were available. The study is small and early phase and uses surrogate biomarkers, so it cannot show effects on cardiovascular events or lifespan. Drug mechanisms were not described in the supplied text.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: